This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by MergersUS Inc. or any other third party regardless of whether such security, product or service is referenced in this website. Furthermore, nothing in this website is intended to provide tax, legal, or investment advice and nothing in this website should be construed as a recommendation to buy, sell, or hold any investment or security or to engage in any investment strategy or transaction.MergersCorp M&A International franchising program is not offered to individuals or entities located in the United States.
The franchising program is offered by MergersUK Limited a UK Company with registered office at 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom.
This company has been in the Colombian market for 19 years, it owns the approved INVIMA registrations.
There is a serious conversations to expand market to Guatemala and 5 more countries in Central America with one big distributor. There are 289 affiliated pharmacies in all main cities of Colombia and in many secondary cities. The CRM is very well organized, with 1397 members between doctors, pharmacies and the institutional market. There are 289 affiliated pharmacies in all main cities of Colombia and in many secondary cities.
Commercial Market
75% of sales are through doctors
25% of sales are Institutional
The company buys the API, the excipients, the packaging and the products, and everything is made by outsourcing in specialized plants in Colombia that are approved by the INVIMA.
Currently, there are 32 products registered and approved by the INVIMA and the Superintendence of Industry and Commerce. Two new products are about to be approved by the INVIMA.
An approval by the INVIMA in Colombia takes an average of 2 years and USD $30.000 of investment to achieve.
This business has 5 nutritional products, of which we own the brand, but not the registry.
Products
o Antibiotics
o Analgesics
o Anti-inflammatory
o Antihistamines
o Cardiovascular
o Nutritional
o Gastroenterology
o Lipid lowering drugs
o Pediatric Products: Antibiotics and Nutritional.
Basic Details
Target Price:
$11,500,000
Gross Revenue
$2,000,000
EBITDA
$450,000
Established
2002
Business ID:
L#20210109
Country
Colombia
City:
Bogota
Detail
Business ID:
L#20210109
Property Type:
Manufacturing, Pharma
Property Status:
For Sale
Target Price:
$11,500,000
Gross Revenue:
$2,000,000
EBITDA:
$450,000
Target Price / Revenue:
5.75x
Target Price / EBITDA:
25.56x
Established:
2002
Business Description:
37 employees, of which 16 are on payroll and the rest are rendering services in different cities.
This company has been in the Colombian market for 19 years, it owns the approved INVIMA registrations.
There is a serious conversations to expand market to Guatemala and 5 more countries in Central America with one big distributor. There are 289 affiliated pharmacies in all main cities of Colombia and in many secondary cities. The CRM is very well organized, with 1397 members between doctors, pharmacies and the institutional market. There are 289 affiliated pharmacies in all main cities of Colombia and in many secondary cities.
Commercial Market
75% of sales are through doctors
25% of sales are Institutional
The company buys the API, the excipients, the packaging and the products, and everything is made by outsourcing in specialized plants in Colombia that are approved by the INVIMA.
Currently, there are 32 products registered and approved by the INVIMA and the Superintendence of Industry and Commerce. Two new products are about to be approved by the INVIMA.
An approval by the INVIMA in Colombia takes an average of 2 years and USD $30.000 of investment to achieve.
This business has 5 nutritional products, of which we own the brand, but not the registry.
Products
o Antibiotics
o Analgesics
o Anti-inflammatory
o Antihistamines
o Cardiovascular
o Nutritional
o Gastroenterology
o Lipid lowering drugs
o Pediatric Products: Antibiotics and Nutritional.
Description
This company has been in the Colombian market for 19 years, it owns the approved INVIMA registrations.
There is a serious conversations to expand market to Guatemala and 5 more countries in Central America with one big distributor. There are 289 affiliated pharmacies in all main cities of Colombia and in many secondary cities. The CRM is very well organized, with 1397 members between doctors, pharmacies and the institutional market. There are 289 affiliated pharmacies in all main cities of Colombia and in many secondary cities.
Commercial Market
The company buys the API, the excipients, the packaging and the products, and everything is made by outsourcing in specialized plants in Colombia that are approved by the INVIMA.
Currently, there are 32 products registered and approved by the INVIMA and the Superintendence of Industry and Commerce. Two new products are about to be approved by the INVIMA.
An approval by the INVIMA in Colombia takes an average of 2 years and USD $30.000 of investment to achieve.
This business has 5 nutritional products, of which we own the brand, but not the registry.
Products
o Antibiotics
o Analgesics
o Anti-inflammatory
o Antihistamines
o Cardiovascular
o Nutritional
o Gastroenterology
o Lipid lowering drugs
o Pediatric Products: Antibiotics and Nutritional.
Basic Details
Target Price:
$11,500,000
Gross Revenue
$2,000,000
EBITDA
$450,000
Established
2002
Business ID:
L#20210109
Country
Colombia
City:
Bogota
Detail
Similar Businesses
Published on June 14, 2021 at 1:08 pm. Updated on December 2, 2023 at 2:02 pm
Environmental Packaging Solutions
TBA
Manufacturing
Water Filling Equipment Industrial Business
TBD
Manufacturing
40-Year-Old MENA Pharmaceutical Manufacturing Company
$45,000,000
Pharma
Water Bottling Company
TBD
Manufacturing
Manufacturer and Distributor of Industrial Equipment & Consumable Supplies
$14,000,000
Manufacturing
Business Specialized in the Production and Sale of PVC Ornamental Panels
€10,087,000
Manufacturing
PREVIOUS PROPERTY
2.40 MW Solar Power Plant with a signed PPA with the Government
NEXT PROPERTY
1M Customers Digital Financial Transaction Platform